查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496118

集落刺激因子（CSF）治疗市场：现况分析与预测（2024-2032）

Colony-Stimulating Factor Therapy Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于肢体缺陷盛行率不断增加，集落刺激因子 (CSF) 治疗市场预计在预测期内将以 10.6% 的复合年增长率强劲增长。集落刺激因子 (CSF) 治疗市场是指专注于开发、生产和销售被称为集落刺激因子的药品的製药业部分。这些药物用于刺激免疫系统因癌症、化疗、骨髓移植或某些感染而减弱的患者产生白血球（特别是粒细胞、巨噬细胞和血小板）。随着全球癌症发生率持续上升，对集落刺激因子的需求也在增加，集落刺激因子通常用作癌症治疗中的支持疗法，以控制化疗引起的中性粒细胞减少症。例如，根据泛美卫生组织估计，到2023年，全球将新增2,000万癌症病例，1,000万人死于癌症。未来 20 年，癌症负担预计将增加约 60%，进一步加重卫生系统、人民和社区的负担。

依类型，市场包括巨噬细胞集落刺激因子（M-CSF）、多集落刺激因子或白血球介素3（IL-3）、粒细胞巨噬细胞集落刺激因子（GM-CSF），它被分类为球状-集落刺激因子（G-CSF）。其中，粒细胞集落刺激因子（G-CSF）细分市场预计将以较高的复合年增长率成长。 G-CSF 通常用作化疗期间的支持疗法，以降低发烧性嗜中性白血球减少症的风险，这是一种以白血球计数低和发烧为特征的严重併发症。随着化疗使用的扩大，对 G-CSF 的需求也在增加，以减少其相关的副作用。此外，G-CSF製剂的不断进步促使了长效製剂的开发，这种製剂需要更少的剂量，增加了患者的便利性和对治疗方案的依从性。

市场依药物分为聚乙二醇非格司亭、TBO非格司亭、沙格司亭、非格司亭等。其中，非格司亭细分市场预计将以较高的复合年增长率成长。非格司亭在刺激接受化疗或骨髓移植的患者产生嗜中性球（一种白血球）方面显示出功效，可降低发烧性嗜中性白血球减少症及其相关併发症的风险。此外，非格司亭已被证明可有效治疗化疗引起的中性粒细胞减少症，包括动员外周血祖细胞进行移植、治疗严重的慢性中性粒细胞减少症以及预防艾滋病毒感染患者的中性粒细胞减少症，它也在各种临床情况中得到了应用。

依用途分为再生障碍性贫血、骨髓移植、嗜中性白血球减少症、化疗引起的嗜中性白血球减少症、放射线引起的中性白血球减少症、週边祖细胞移植等。化疗相关的中性粒细胞减少症预计在未来一段时间内将以高复合年增长率增长。随着全球癌症发生率的上升，越来越多的患者正在接受化疗，这通常会导致中性粒细胞减少症。化疗药物会抑制骨髓产生白血球（包括嗜中性球）的能力，使患者更容易受到感染。此外，化疗不仅越来越多地被用作癌症的主要治疗，而且还被用作与手术或放射治疗相结合的辅助或新辅助治疗。此类化疗的广泛应用导致中性粒细胞减少症风险族群的增加。

依最终用户划分，市场分为医院、专科诊所、家庭医疗保健等。 2023年的市场中，医院领域将占据压倒性占有率。医院是癌症、自体免疫疾病和严重感染等严重疾病患者的初级护理机构，这些患者通常需要使用集落刺激因子 (CSF) 疗法作为支持性护理。随着这些疾病的全球发生率不断增加，医院环境中对集落刺激因子的需求也增加。

根据销售管道，市场分为医院药局、零售药局和网路药局。医院药房预计将在一段时间内以较高的复合年增长率增长。医院药房充当医院内配药的中心中心。医院药房备有多种药物，包括促定植剂，并为接受医院护理的患者及时提供这些药物。此外，医院药房配备了经过专门培训和专业知识的药剂师和药剂师技术人员，可以管理复杂的药物治疗方案，包括集落刺激因子等支持性治疗。

为了更瞭解集落刺激因子（CSF）治疗产业的市场实施情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利） ，欧洲其他地区），根据亚太地区（中国、日本、印度、亚太地区其他地区）、世界其他地区的全球影响力进行分析。北美在市场上占据主导地位，预计这一趋势在预测期内将持续下去。北美集落刺激因子（CSF）治疗市场由多种因素驱动。与其他地区相比，北美的癌症发生率相对较高，导致大量患者需要化疗和支持性治疗，包括集落刺激因子。癌症流行正在推动该地区对集落刺激因子 (CSF) 治疗的需求。此外，北美人口正在老化，癌症和其他需要化疗和支持性护理的与年龄相关的疾病的盛行率不断增加。随着人口老化，对集落刺激因子的需求不断增加，以控制治疗相关的副作用并改善患者的治疗效果。

目录

第一章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第二章研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对集落刺激因子 (CSF) 治疗市场的影响

第 6 章全球集落刺激因子 (CSF) 治疗市场收入，2022-2032 年

第 7 章市场分析：依类型

  • 巨噬细胞集落刺激因子 (M-CSF)
  • 多集落刺激因子，或白血球介素 3 (IL-3)
  • 粒细胞巨噬细胞集落刺激因子 (GM-CSF)
  • 粒细胞集落刺激因子 (G-CSF)

第 8 章市场分析：依药物

  • 培非格司亭
  • Tbo非格司亭
  • 沙格司汀
  • 非格司亭
  • 其他

第 9 章市场分析：依应用

  • 再生不良性贫血
  • 骨髓移植
  • 嗜中性白血球减少症
  • 化疗相关的中性白血球减少症
  • 辐射相关的中性白血球减少症
  • 週边血干细胞移植

第 10 章市场分析：依最终使用者划分

  • 医院
  • 专科诊所
  • 家庭医疗护理
  • 其他

第 11 章市场分析：依通路

  • 医院药房
  • 零售药局
  • 网路药局

第 12 章市场分析：依地区

  • 北美集落刺激因子 (CSF) 治疗市场
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲集落刺激因子 (CSF) 治疗市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区集落刺激因子 (CSF) 治疗市场
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区的集落刺激因子（CSF）治疗市场

第 13 章集落刺激因子 (CSF) 治疗市场动态

  • 市场驱动因素
  • 市场课题
  • 影响分析

第 14 章集落刺激因子 (CSF) 治疗市场机会

第 15 章集落刺激因子 (CSF) 治疗市场趋势与见解

第十六章需求方与供给方分析

  • 需求方分析
  • 供给面分析

第十七章价值链分析

第十八章价格分析

第十九章竞争场景

  • 竞争状况
    • 波特五力分析

第20章公司简介

  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc

第 21 章免责声明

简介目录
Product Code: UMHE212756

The Colony-stimulating factor therapy Market is expected to grow at a strong CAGR of 10.6% during the forecast period owing to increasing prevalence of limb loss. The colony stimulating factor (CSF) therapy market refers to the segment of the pharmaceutical industry focused on the development, production, and sale of medications known as colony stimulating factors. These medications are used to stimulate the production of white blood cells (specifically granulocytes, macrophages, and platelets) in patients whose immune systems are compromised due to conditions such as cancer, chemotherapy, bone marrow transplant, or certain infections. As the incidence of cancer continues to rise globally, the demand for colony stimulating factors, which are often used as supportive care in cancer treatment to manage chemotherapy-induced neutropenia, is also increasing. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

Based on the Type, the market has been categorized into macrophage-colony-stimulating factor (M-CSF), multiple-colony-stimulating factor, or interleukin 3 (IL-3), granulocyte-macrophage-colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF). Among them, the granulocyte-colony-stimulating factor (G-CSF) segment is expected to grow at a higher CAGR in the market. G-CSFs are commonly used as supportive therapy during chemotherapy to reduce the risk of febrile neutropenia, a potentially serious complication characterized by a low white blood cell count and fever. As the use of chemotherapy expands, so does the demand for G-CSF to mitigate associated side effects. Moreover, Continuous advancements in G-CSF formulations have led to the development of long-acting versions that require less frequent administration, improving patient convenience and adherence to treatment regimens

Based on the drug, the market has been categorized into pegfilgrastim, tbo-filgrastim, sargramostim, filgrastim, others. Among them, the filgrastim segment is expected to grow at a higher CAGR in the market. Filgrastim has a well-established track record of efficacy in stimulating the production of neutrophils (a type of white blood cell) in patients undergoing chemotherapy or bone marrow transplantation, thereby reducing the risk of febrile neutropenia and its associated complications. Moreover, Filgrastim is indicated for a variety of clinical scenarios beyond chemotherapy-induced neutropenia, including mobilization of peripheral blood progenitor cells for transplantation, treatment of severe chronic neutropenia, and prevention of neutropenia in patients with HIV infection, expanding its market potential.

By application, the market is categorized into aplastic anemia, bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy, neutropenia associated with radiation, peripheral progenitor cell transplantation. The neutropenia associated with chemotherapy is anticipated to grow with high CAGR during the forthcoming period. With the rising incidence of cancer globally, more patients are undergoing chemotherapy, which often leads to neutropenia. Chemotherapy drugs can suppress the bone marrow's ability to produce white blood cells, including neutrophils, leaving patients vulnerable to infections. Moreover, Chemotherapy is being increasingly utilized not only as a primary treatment for cancer but also in adjuvant and neoadjuvant settings, in combination with surgery or radiation therapy. This broader application of chemotherapy contributes to a larger population at risk of developing neutropenia.

Based on end-users, the market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held a dominant share of the market in 2023. Hospitals are the primary care facilities for patients with serious illnesses such as cancer, autoimmune diseases, and severe infections, which often necessitate the use of colony stimulating factor therapy as supportive care. With the growing incidence of these conditions globally, there is a corresponding increase in the demand for colony stimulating factors in hospital settings.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies are anticipated to grow with high CAGR during the forthcoming period. Hospital pharmacies serve as centralized hubs for medication dispensing within the hospital setting. They stock a wide range of pharmaceutical products, including colony stimulating factors, and provide timely access to these medications for patients undergoing treatment in the hospital. Moreover, hospital pharmacies are staffed with pharmacists and pharmacy technicians who have specialized training and expertise in managing complex medication regimens, including supportive therapies like colony stimulating factors.

For a better understanding of the market adoption of the colony-stimulating factor therapy industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America holds the dominant share of the market and is expected to do so even in the forecast period. The North America colony-stimulating factor therapy market is being driven by several factors. North America has a relatively high incidence of cancer compared to other regions, contributing to a large patient population requiring chemotherapy and supportive care, including colony stimulating factors. The prevalence of cancer drives the demand for colony stimulating factor therapy in the region. Moreover, the aging population in North America is driving an increase in the prevalence of cancer and other age-related conditions requiring chemotherapy and supportive therapies. As the population ages, there is a higher demand for colony stimulating factors to manage treatment-related side effects and improve patient outcomes.

Some of the major players operating in the market include Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Amgen Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Colony-Stimulating Factor Therapy Market
  • 2.2. Research Methodology of the Colony-Stimulating Factor Therapy Market
  • 2.4. Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE COLONY-STIMULATING FACTOR THERAPY MARKET

6.GLOBAL COLONY-STIMULATING FACTOR THERAPY MARKET REVENUE, 2022-2032F

7.MARKET INSIGHTS BY TYPE

  • 7.1. Macrophage-Colony-Stimulating Factor (M-CSF)
  • 7.2. Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
  • 7.3. Granulocyte-Macrophage-Colony-Stimulating Factor (GM-CSF)
  • 7.4. Granulocyte-Colony-Stimulating Factor (G-CSF)

8.MARKET INSIGHTS BY DRUG

  • 8.1. Pegfilgrastim
  • 8.2. Tbo-filgrastim
  • 8.3. Sargramostim
  • 8.4. Filgrastim
  • 8.5. Others

9.MARKET INSIGHTS BY APPLICATION

  • 9.1. Aplastic Anemia
  • 9.2. Bone Marrow Transplantation
  • 9.3. Neutropenia
  • 9.4. Neutropenia Associated with Chemotherapy
  • 9.5. Neutropenia Associated with Radiation
  • 9.6. Peripheral Progenitor Cell Transplantation

10.MARKET INSIGHTS BY END-USERS

  • 10.1. Hospitals
  • 10.2. Specialty Clinics
  • 10.3. Homecare
  • 10.4. Others

11.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 8.1. Hospital Pharmacies
  • 8.2. Retail Pharmacies
  • 8.3. Online Pharmacies

12.MARKET INSIGHTS BY REGION

  • 12.1 NORTH AMERICA COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.1.1. U.S.
    • 12.1.2. Canada
    • 12.1.3. Rest of North America
  • 12.2 EUROPE COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.2.1. Germany
    • 12.2.2. U.K.
    • 12.2.3. France
    • 12.2.4. Italy
    • 12.2.5. Spain
    • 12.2.6. Rest of Europe
  • 12.3 ASIA PACIFIC COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.3.1. China
    • 12.3.2. Japan
    • 12.3.3. India
    • 12.3.4. Rest of Asia-Pacific
  • 12.4 REST OF THE WORLD COLONY-STIMULATING FACTOR THERAPY MARKET

13.COLONY-STIMULATING FACTOR THERAPY MARKET DYNAMICS

  • 13.1. Market Drivers
  • 13.2. Market Challenges
  • 13.3. Impact Analysis

14.COLONY-STIMULATING FACTOR THERAPY MARKET OPPORTUNITIES

15.COLONY-STIMULATING FACTOR THERAPY MARKET TRENDS & INSIGHTS

16.DEMAND AND SUPPLY SIDE ANALYSIS

  • 16.1. Demand Side Analysis
  • 16.2. Supply Side Analysis

17.VALUE CHAIN ANALYSIS

18.PRICING ANALYSIS

19.COMPETITIVE SCENARIO

  • 19.1. Competitive Landscape
    • 19.1.1 Porter's Five forces analysis

20.COMPANY PROFILED

  • 20.1. Sanofi
  • 20.2. Novartis AG
  • 20.3. Teva Pharmaceutical Industries Ltd.
  • 20.4. Pfizer Inc.
  • 20.5. GlaxoSmithKline plc
  • 20.6. Dr. Reddy's Laboratories Ltd.
  • 20.7. Amgen Inc.
  • 20.8. Merck KGaA
  • 20.9. Takeda Pharmaceutical Company Limited
  • 20.10. Thermo Fisher Scientific Inc

21.DISCLAIMER